Client Story

EUSA Pharma

London-based pharmaceutical company EUSA Pharma markets new drugs to combat serious diseases.

 

We were informed by the equity firm Essex Woodlands, which had invested in EUSA Pharma, and by the latter company itself that it was on the look-out for innovative drugs as part of its growth strategy.

Strategy and Growth
Buy-Side Advisory
Healthcare and Life Sciences
Reading Time 3 minutes
Key Results
Purchase of global marketing rights to dinutuximab beta
by EUSA Pharma, quickly managed to obtain European approval.
Development of dinutuximab beta
for the treatment of neuroblastoma, the second most common solid tumor in children, by the Austrian biotech company Apeiron.
Approval of the drug
in the pipeline in the USA (as of September 2017).

The challenge

  • We were informed by the equity firm Essex Woodlands, which had invested in EUSA Pharma, and by the latter company itself that it was on the look-out for innovative drugs as part of its growth strategy.
  • EUSA Pharma was willing to acquire the rights to drugs for which approval had yet to be granted. Seizing the initiative, our pharmaceutical team went in search of a suitable drug.
Dark blue Background with multiple viruses in the front.

The solution

Thanks to its network of medics and pharmaceutical experts, the team was able to identify Apeiron´s immunotherapy for the treatment of brain tumors as a suitable target for purchase. Apeiron itself lacked the resources for marketing.

The team of consultants arranged a meeting and EUSA Pharma lost no time in taking action: European approval was applied for shortly after the completion of due diligence and conclusion of the purchase contract, and granted soon afterwards. 

The deal would not have come about without the initiative, wealth of knowledge and network of them.
Lee Morley
CEO of EUSA Pharma 

Passion for resultsWhat our 
client says

Ready for tomorrow?Get in touch and see how our team can help you.

What's new?You might also be interested in...

Insight
Article
July 2025
Private Equity value creation in a challenging environment
In today's challenging macroeconomic environment, Private Equity firms must adopt a structured, integrated approach to value creation. Success increasingly depends on carefully orchestrating operational, strategic, and financing levers tailored to each portfolio company. A survey with 50+ Private Equity firms confirms: Operational value creation is becoming the top priority, especially driving profitability through operational, organizational, and commercial excellence.
Insight
Brochure
July 2025
M&A Industry Snapshot: PropTech
We are committed to delivering actionable insights and thought leadership that empower businesses to navigate the evolving PropTech landscape. This spotlight explores the transformative role of M&A in the sector, highlighting current trends, a standout deal with recent transactions, sector valuation multiples, and our strong track record.
Insight
Article
June 2025
From expense to asset: the contact center transformation
In today’s hyper-connected world, contact centers are facing an inflection point. Once viewed purely as operational cost centers, they now stand at a strategic crossroads. With rising customer expectations, rapid advancements in AI and automation, and increasing talent challenges, companies must decide: will the contact center remain a reactive support function – or evolve into a proactive engine for growth, loyalty, and insight? Forward-thinking organizations are already reshaping their approach.